Entyvio® Intravenous (vedolizumab)

Entyvio (vedolizumab) IV is covered for adults ≥18 with moderately‑to‑severely active Crohn’s disease or ulcerative colitis (mesalamine products do not count as systemic therapy); approvals are for 12 months with dosing 300 mg IV at Weeks 0, 2, 6 then every 8 weeks. Initial authorization requires a gastroenterologist prescriber/consult and disease‑specific criteria (Crohn’s: fistulas, prior ileocolonic resection, trial of another systemic agent or corticosteroid/use or steroid contraindication; UC: trial of another systemic agent or, for pouchitis, trial of antibiotic/probiotic/corticosteroid or mesalamine enema) with documentation of prior therapies/outcomes, and reauthorization requires ≥6 months on therapy plus objective or symptomatic clinical benefit (restarts or <6 months on therapy are treated as initial requests).

"Entyvio Intravenous is indicated in adults for the treatment of: moderately to severely active ulcerative colitis."